Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Allogeneic NK cells
DRUG: Rituximab
DRUG: Tafasitamab
DRUG: Interleukin-2
DRUG: Fludarabine/cyclophosphamide

Sponsor

Paolo Caimi, MD

Collaborators

[object Object]